Lack of Cell Cycle Inhibitor p21 and Low CD4
Adaptive Immunity
/ drug effects
Adult
Age Factors
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cell Proliferation
/ drug effects
Cells, Cultured
Cyclin-Dependent Kinase Inhibitor p21
/ deficiency
Fetal Blood
/ cytology
Flow Cytometry
Humans
Immunomagnetic Separation
Infant, Newborn
Interferon-beta
/ metabolism
Primary Cell Culture
Receptor, Interferon alpha-beta
/ antagonists & inhibitors
Signal Transduction
/ drug effects
CD4 T cells
cell cycle
cyclic-dependent kinase inhibitor/p21
immunity
interferon beta
newborns
proliferation
respiratory syncytial virus
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
01
2021
accepted:
18
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Type I IFNs, such as interferon alpha and interferon beta, are key regulators of the adaptive immune response during infectious diseases. Type I IFNs are induced upon infection, bind interferon α/β receptors on T-cells and activate intracellular pathways. The activating and inhibitory consequences of type I IFN-signaling are determined by cell type and cellular environment. The neonatal immune system is associated with increased vulnerability to infectious diseases which could partly be explained by an immature CD4
Identifiants
pubmed: 33912177
doi: 10.3389/fimmu.2021.652965
pmc: PMC8071872
doi:
Substances chimiques
CDKN1A protein, human
0
Cyclin-Dependent Kinase Inhibitor p21
0
IFNAR1 protein, human
0
IFNAR2 protein, human
0
Receptor, Interferon alpha-beta
156986-95-7
Interferon-beta
77238-31-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
652965Informations de copyright
Copyright © 2021 Jans, Unger, Raeven, Simonetti, Eleveld, de Groot, de Jonge and Ferwerda.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Exp Cell Res. 1999 Feb 1;246(2):280-9
pubmed: 9925742
Cell Death Differ. 2007 Sep;14(9):1561-75
pubmed: 17627286
Mol Cell Biol. 2006 Mar;26(5):1888-97
pubmed: 16479007
PLoS One. 2012;7(5):e36909
pubmed: 22615843
Sci Rep. 2015 Jan 09;5:7691
pubmed: 25573673
Immunology. 2007 May;121(1):29-39
pubmed: 17239199
Sci Rep. 2016 Dec 05;6:38411
pubmed: 27917918
J Virol. 2011 Jun;85(12):5929-39
pubmed: 21471240
Immunol Res. 2014 Aug;59(1-3):109-17
pubmed: 24838148
Immunology. 2006 Apr;117(4):433-42
pubmed: 16556256
J Allergy Clin Immunol. 2017 Jun;139(6):1997-2000.e4
pubmed: 27931976
J Biol Chem. 2011 Mar 11;286(10):8644-8654
pubmed: 21209082
Nat Rev Cancer. 2009 Jun;9(6):400-14
pubmed: 19440234
Immunol Rev. 2012 Nov;250(1):317-34
pubmed: 23046138
Cytokine. 2015 Dec;76(2):458-464
pubmed: 26253531
J Biol Chem. 1998 Apr 3;273(14):8003-8
pubmed: 9525899
Int J Oncol. 2007 Sep;31(3):613-20
pubmed: 17671689
Oncogene. 2006 Aug 28;25(38):5220-7
pubmed: 16936740
Nat Med. 2017 Jan 6;23(1):18-27
pubmed: 28060797
Eur J Immunol. 2006 May;36(5):1241-53
pubmed: 16568497
J Neuroimmunol. 1996 Jul;67(2):111-8
pubmed: 8765333
J Immunol. 2001 Oct 1;167(7):4067-74
pubmed: 11564828
Nat Med. 2014 Oct;20(10):1206-10
pubmed: 25242415
J Biol Chem. 2010 Nov 5;285(45):34677-85
pubmed: 20736166
J Clin Pathol. 1997 Aug;50(8):645-53
pubmed: 9301547
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
J Immunol. 2002 Mar 15;168(6):2820-7
pubmed: 11884451
Genes Dev. 1995 Apr 15;9(8):935-44
pubmed: 7774811
Dev Cell. 2008 Feb;14(2):159-69
pubmed: 18267085